ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Nausea and Vomiting

Nausea and Vomiting

The FDA has approved the first single-dose intravenous NK1 receptor antagonist, fosaprepitant dimeglumine (Emend), for the treatment of nausea and vomiting that can accompany the use of moderately and highly emetogenic chemotherapy.

The American Society of Clinical Oncology (ASCO) updated their antiemetic guideline to include the use of a novel antiemetic combination for cancer patients.

A phase III study showed that APF530 could improve control of emesis in cancer patients receiving highly emetogenic chemotherapy.

The US Food and Drug Administration has approved rolapitant for the prevention of delayed phase nausea and vomiting associated with chemotherapy.

The FDA has approved combined netupitant and palonosetron (Akynzeo) for the treatment of chemotherapy-related nausea and vomiting in patients with cancer.

Rolapitant added to granisetron/dexamethasone helped prevented chemotherapy-induced nausea and vomiting in patients treated with cisplatin-based chemotherapy, according to a study at the ESMO 2014 Congress.

New research confirms that use of metoclopramide, commonly used for nausea and vomiting, in early pregnancy does not increase risk of major malformations.

Pages

Subscribe to Nausea and Vomiting on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.